254 related articles for article (PubMed ID: 33379241)
21. Circulating long non-coding RNAs HOTAIR, Linc-p21, GAS5 and XIST expression profiles in diffuse large B-cell lymphoma: association with R-CHOP responsiveness.
Senousy MA; El-Abd AM; Abdel-Malek RR; Rizk SM
Sci Rep; 2021 Jan; 11(1):2095. PubMed ID: 33483590
[TBL] [Abstract][Full Text] [Related]
22. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint.
Zhao L; Liu Y; Zhang J; Liu Y; Qi Q
Cell Death Dis; 2019 Sep; 10(10):731. PubMed ID: 31570691
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity.
Peng W; Fan H; Wu G; Wu J; Feng J
Clin Exp Med; 2016 May; 16(2):177-82. PubMed ID: 25864113
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of long non-coding RNA TUG1 suppresses tumor growth by promoting ubiquitination of MET in diffuse large B-cell lymphoma.
Cheng H; Yan Z; Wang X; Cao J; Chen W; Qi K; Zhou D; Xia J; Qi N; Li Z; Xu K
Mol Cell Biochem; 2019 Nov; 461(1-2):47-56. PubMed ID: 31338678
[TBL] [Abstract][Full Text] [Related]
25. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma.
Peng W; Wu J; Feng J
Biomed Pharmacother; 2016 Apr; 79():188-93. PubMed ID: 27044827
[TBL] [Abstract][Full Text] [Related]
26. Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review.
Decruyenaere P; Offner F; Vandesompele J
Exp Hematol Oncol; 2021 Feb; 10(1):13. PubMed ID: 33593440
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
28. LncRNA SNHG8 Promotes Proliferation and Inhibits Apoptosis of Diffuse Large B-Cell Lymphoma
Yu B; Wang B; Wu Z; Wu C; Ling J; Gao X; Zeng H
Front Oncol; 2021; 11():650287. PubMed ID: 33816305
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma.
Su Y; Sun B; Lin X; Zhao X; Ji W; He M; Qian H; Song X; Yang J; Wang J; Chen J
Oncotarget; 2016 Aug; 7(31):49143-49155. PubMed ID: 27172795
[TBL] [Abstract][Full Text] [Related]
30. Long Non-Coding RNAs Guide the Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy.
Dahl M; Kristensen LS; Grønbæk K
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30134619
[TBL] [Abstract][Full Text] [Related]
31. Long non-coding RNA HAGLROS promotes the development of diffuse large B-cell lymphoma via suppressing miR-100.
Shu L; Guo K; Lin ZH; Liu H
J Clin Lab Anal; 2022 Jan; 36(1):e24168. PubMed ID: 34888946
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
33. Knockdown of the long non-coding RNA CACNA1G-AS1 enhances cytotoxicity and apoptosis of human diffuse large B cell lymphoma by regulating miR-3160-5p.
Zhou Q; Zhang Y; Zhao M; Zhao X; Xue H; Xiao S
Exp Ther Med; 2022 Oct; 24(4):627. PubMed ID: 36160896
[TBL] [Abstract][Full Text] [Related]
34. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with
Uryu H; Mishima Y; Tsuyama N; Yokoyama M; Nishimura N; Fukuta T; Shirouchi Y; Okabe T; Inoue N; Takeuchi K; Terui Y
Leuk Lymphoma; 2021 Sep; 62(9):2141-2150. PubMed ID: 33749498
[TBL] [Abstract][Full Text] [Related]
35. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
[TBL] [Abstract][Full Text] [Related]
36. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
Yang X; Min X; He W
Medicine (Baltimore); 2018 May; 97(21):e10845. PubMed ID: 29794780
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
38. Diffuse large B-cell lymphoma.
Martelli M; Ferreri AJ; Agostinelli C; Di Rocco A; Pfreundschuh M; Pileri SA
Crit Rev Oncol Hematol; 2013 Aug; 87(2):146-71. PubMed ID: 23375551
[TBL] [Abstract][Full Text] [Related]
39. Selective delivery of T22-PE24-H6 to CXCR4
Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
[No Abstract] [Full Text] [Related]
40. REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon
Welslau M; Kubuschok B; Topaly J; Otremba B; Wolff T; Bryn G
Ther Adv Hematol; 2023; 14():20406207231183765. PubMed ID: 37492394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
